{"ticker": {"uuid": "bcb67560-2ecc-4e50-a0b7-07e5a42bb64a", "symbol": "RCUS", "name": "Arcus Biosciences Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arcus-biosciences-host-conference-call-200500745.html", "source_name": "Business Wire", "published_at": "2026-07-21T20:05:00+00:00", "published_display": "21 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences to Discuss Cancer and Autoimmune Pipeline Aug. 5", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQNWFTeFhSNWdjY3c3YjZtX0pxdk9nb0g0NmtLSC1sYUppOERldFI1Q2NGMmtCU08xTDVScEVaN2U4ZXdzdDZOS2RKYTlScGhTR2pUX1NHWWhBRFBKSDNodzJINlVnTXN6UDNQdENBUjhEbjZPQVh1QnU2UkxOSEdINlplU2MzUlpPSDNkNjZSVTR1dGRNTXdvajQwc3ZmY1NxSzRYZEdQYXJyV1dpTTBDQThDRHlSUnVqMlNlVkFGbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T20:05:00+00:00", "published_display": "21 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?", "summary": "HC Wainwright has increased its price target for Arcus Biosciences (NASDAQ: RCUS) from $32 to $45, while maintaining a Buy rating. This adjustment reflects the company's aggressive expansion into first-line clear cell renal cell carcinoma (ccRCC) development with its drug casdati", "url": "https://www.benzinga.com/analyst-stock-ratings/price-target/26/07/60562867/arcus-biosciences-analyst-bump-price-forecast-by-33", "source_name": "Benzinga", "published_at": "2026-07-20T19:09:34", "published_display": "20 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences Jumps 5.5% After HC Wainwright & Co. Maintains Buy", "summary": "Arcus Biosciences (RCUS) saw its stock jump 5.5% to $28.88 on Monday after HC Wainwright & Co. raised its price target from $32 to $45 while maintaining a Buy rating. This bullish analyst action, coupled with increased trading volume, signifies renewed investor confidence in the ", "url": "https://news.alphastreet.com/arcus-biosciences-jumps-5-5-after-hc-wainwright-co-maintains-buy/amp/", "source_name": "AlphaStreet", "published_at": "2026-07-20T17:09:34", "published_display": "20 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 87, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises Arcus Biosciences stock price target to $45", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNb0ZFeDJRc0RPZ0xzN0VldW81clZHUXh2Yjg5b0pPWUlidGNNUXZSWkV0VU5mSHJ3eDFpY1B5UV9ZcU5BUDgzR3JNOUlocGJQS19XeDZPSXN4UjNZdmIxWHpOamx0X2tpSXkwVGtJbnJVSVh1R09BX3B5TEp3d0xfODRQSFpuLXNqRWx0cW1NTDVkbXVMcF81T3llSnd4SVgtT1ozV1d5OXE5UDZLS05hZ0t2TFJzWkJwREFyVXk1cWU?oc=5", "source_name": "Investing.com", "published_at": "2026-07-20T12:02:09+00:00", "published_display": "20 Jul 2026 12:02", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises Arcus Biosciences stock price target to $45 By Investing.com", "summary": "H.C. Wainwright has increased its price target for Arcus Biosciences (NASDAQ:RCUS) to $45 from $32, reiterating a Buy rating based on the company's progress in immuno-oncology, particularly with its drug casdatifan for clear cell renal cell carcinoma. The firm highlighted casdati", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-raises-arcus-biosciences-stock-price-target-to-45-93CH-4741659", "source_name": "Investing.com Canada", "published_at": "2026-07-20T12:09:34", "published_display": "20 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences (RCUS) Proxy filing Summary", "summary": "This article summarizes Arcus Biosciences' proxy filing from April 21, 2026, outlining key voting matters for its annual meeting on June 11, 2026. Shareholders are asked to elect four directors, ratify Ernst & Young LLP as the independent auditor, and approve named executive offi", "url": "https://quartr.com/events/arcus-biosciences-inc-rcus-proxy-filing_Fk6vjbMI", "source_name": "Quartr", "published_at": "2026-07-16T22:40:51", "published_display": "16 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "This Insider Has Just Sold Shares In Arcus Biosciences", "summary": "Arcus Biosciences co-founder and President, Juan Jaen, recently sold approximately US$2.0 million worth of shares at an average price of US$29.63, representing 5.9% of his total holding. While this is the largest insider sale in the past year, it occurred around the current share", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rcus/arcus-biosciences/news/this-insider-has-just-sold-shares-in-arcus-biosciences", "source_name": "Simply Wall Street", "published_at": "2026-07-15T12:10:12", "published_display": "15 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Arcus Biosciences Inc For: 13 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Arcus Biosciences Inc. on July 13th, 2026. It notes Arcus Biosciences (RCUS) stock price performance and includes general market data for various indices, commodities, and individual stocks. The publication date is sp", "url": "https://au.investing.com/news/stock-market-news/form-4-arcus-biosciences-inc-for-13-july-93CH-4530875", "source_name": "Investing.com Australia", "published_at": "2026-07-14T07:44:00", "published_display": "14 Jul 2026 07:44", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run", "summary": "Jonathan Ponciano reports on an insider sale at Arcus Biosciences, where president Juan C. Jaen sold 68,569 shares through a trust under a Rule 10b5-1 trading plan. Despite the sale, Jaen retains a significant stake of approximately 1.2 million shares. The article emphasizes that", "url": "https://finance.yahoo.com/markets/stocks/articles/arcus-insider-sold-68-569-232917867.html", "source_name": "Market source", "published_at": "2026-07-13T23:09:41", "published_display": "13 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences Insider Sold Shares Worth $2,031,919, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/arcus-biosciences-insider-sold-shares-214356143.html", "source_name": "MT Newswires", "published_at": "2026-07-13T21:43:56+00:00", "published_display": "13 Jul 2026 21:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences (RCUS) president trades 68,569 shares under 10b5-1 plan", "summary": "Arcus Biosciences President Juan C. Jaen reported the sale of 68,569 shares of common stock on July 9-10, 2026, through a trust under a Rule 10b5-1 trading plan. The sales occurred at weighted-average prices between $28.61 and $30.05 per share. Despite these sales, Jaen retains s", "url": "https://www.stocktitan.net/sec-filings/RCUS/form-4-arcus-biosciences-inc-insider-trading-activity-8e32d6cba75c.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:41:42", "published_display": "13 Jul 2026 21:41", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form 144 Arcus Biosciences For: 9 July By Investing.com", "summary": "This article announces the filing of Form 144 for Arcus Biosciences (RCUS) on July 9, by Investing.com. Form 144 filings indicate an intent to sell restricted or control securities. This brief notice provides a direct-to-the-point update regarding this specific financial action r", "url": "https://ca.investing.com/news/stock-market-news/form-144-arcus-biosciences-for-9-july-93CH-4728311", "source_name": "Investing.com Canada", "published_at": "2026-07-09T23:11:45", "published_display": "09 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trust files proposed RCUS Class A sales (RCUS) \u2014 multiple dates and amounts", "summary": "The Juan Carlos Jaen and Anita Galeana 2000 Trust has filed multiple Form 144 notices for proposed sales of Arcus Biosciences (RCUS) Class A Common Stock. These include sales on June 22, 23, 24, and July 9, 2026, totaling numerous shares and significant proceeds. The filing also ", "url": "https://www.stocktitan.net/sec-filings/RCUS/144-arcus-biosciences-inc-sec-filing-ea357c9b481d.html", "source_name": "Stock Titan", "published_at": "2026-07-09T22:10:04", "published_display": "09 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences Announces New Employment Inducement Grants", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arcus-biosciences-announces-employment-inducement-203500812.html", "source_name": "Business Wire", "published_at": "2026-07-09T20:35:00+00:00", "published_display": "09 Jul 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences awards stock options to five new employees", "summary": "Arcus Biosciences (RCUS) announced on July 9, 2026, that its Compensation Committee granted stock options and restricted stock units to five new employees. These inducement awards allow employees to purchase a total of 16,060 shares at $30.26 per share and acquire 8,080 shares of", "url": "https://www.stocktitan.net/news/RCUS/arcus-biosciences-announces-new-employment-inducement-a4qpq00phbzo.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:10:04", "published_display": "09 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences (RCUS) H.C. Wainwright 27th Annual Global Investment Conference summary", "summary": "Arcus Biosciences (RCUS) presented at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its pipeline with three programs and five Phase 3 studies, supported by significant financing from partners. A key focus is castatinopathy, a next-generation HIF2\u03b1 inh", "url": "https://quartr.com/events/arcus-biosciences-inc-rcus-h-c-wainwright-27th-annual-global-investment-conference_Fk6vzmF9", "source_name": "Quartr", "published_at": "2026-07-09T10:11:18", "published_display": "09 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences (RCUS) Gains Fresh Attention As Nature Study Puts Valuation Back In Focus", "summary": "Arcus Biosciences (RCUS) is drawing renewed attention following a Nature study on its HIF-2a inhibitor casdatifan, which showed a link between serum EPO suppression and clinical outcomes in metastatic kidney cancer. The company's stock has seen strong recent performance, with a 3", "url": "https://www.sahmcapital.com/news/content/arcus-biosciences-rcus-gains-fresh-attention-as-nature-study-puts-valuation-back-in-focus-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-05T19:41:21", "published_display": "05 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Arcus Biosciences (RCUS) Nature\u2011Published ARC\u201120 Kidney Cancer Biomarker Data", "summary": "Arcus Biosciences' Nature-published ARC-20 study data shows that casdatifan monotherapy for metastatic clear cell renal cell carcinoma links deeper HIF\u20112\u03b1 inhibition to changes in the biomarker serum EPO, with greater EPO suppression associated with higher response rates and long", "url": "https://www.sahmcapital.com/news/content/how-investors-are-reacting-to-arcus-biosciences-rcus-naturepublished-arc20-kidney-cancer-biomarker-data-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-04T19:09:07", "published_display": "04 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Arcus Bioscience (RCUS)", "summary": "This article analyzes the historical performance of investing $1,000 in Arcus Bioscience (RCUS) over various periods, showing significant returns in the last year but more modest or negative returns over longer durations. It details Arcus Bioscience's focus on developing cancer a", "url": "https://www.stocktitan.net/tools/stock-return-calculator/RCUS", "source_name": "Stock Titan", "published_at": "2026-07-04T06:40:17", "published_display": "04 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bristol-myers-squibb-bmy-joins-213544982.html", "source_name": "Insider Monkey", "published_at": "2026-07-01T21:35:44+00:00", "published_display": "01 Jul 2026 21:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RCUS - Arcus Biosciences Inc Latest SEC Filings", "summary": "This article provides a snapshot of Arcus Biosciences Inc (RCUS) with its latest financial data, key performance indicators, and market statistics as of July 1, 2026. It covers various metrics including market capitalization, income, sales, insider and institutional ownership, pr", "url": "https://finviz.com/stock?t=RCUS&ta=1&p=d&ty=lf&r=m1&page=20", "source_name": "Finviz", "published_at": "2026-07-01T20:39:08", "published_display": "01 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nature study links a kidney-cancer biomarker to casdatifan benefit", "summary": "Arcus Biosciences announced new research published in Nature, linking clinical outcomes of patients treated with the HIF-2a inhibitor casdatifan to changes in the biomarker erythropoietin (EPO). The study, ARC-20, showed that deeper suppression of serum EPO correlated with higher", "url": "https://www.stocktitan.net/news/RCUS/new-research-published-in-nature-links-clinical-activity-with-hif-2a-x90xpa3ikiee.html", "source_name": "Stock Titan", "published_at": "2026-07-01T15:10:52", "published_display": "01 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Arcus Biosciences, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold shares of Arcus Biosciences, Inc. (RCUS). It provides a detailed table including each ETF's market value, weight of RCUS stock in the fund, issuer, management style, focus, expense ratio, assets under management (A", "url": "https://www.tradingview.com/symbols/NYSE-RCUS/etfs/", "source_name": "TradingView", "published_at": "2026-06-30T04:40:04", "published_display": "30 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences, Inc. Actuals & Estimates (NYSE:RCUS)", "summary": "This article provides an overview of Arcus Biosciences, Inc. (RCUS) stock performance, analyst estimates, and financial data. It details recent stock price movements, historical highs and lows, market capitalization, and upcoming earnings dates. The company's financial actuals an", "url": "https://www.tradingview.com/symbols/NYSE-RCUS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T16:09:26", "published_display": "26 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RCUS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for Arcus Biosciences, Inc. (RCUS) stock, including analyst price targets and future predictions. It details the stock's current price, historical performance, earnings reports, revenue, market capitalization, and volatility, along with answers to ", "url": "https://www.tradingview.com/symbols/NYSE-RCUS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:40:21", "published_display": "26 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus awards two new employees stock options, RSUs", "summary": "Arcus Biosciences, a clinical-stage biopharmaceutical company, announced it has granted stock options and restricted stock units to two new employees. These inducement awards, totaling 18,400 options and 9,250 RSUs, were issued under the company's 2020 Inducement Plan, consistent", "url": "https://www.stocktitan.net/news/RCUS/arcus-biosciences-announces-new-employment-inducement-wyo6agvwf8c1.html", "source_name": "Stock Titan", "published_at": "2026-06-25T15:09:39", "published_display": "25 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Arcus Biosciences Inc For: 24 June By Investing.com", "summary": "This article reports on a Form 4 filing for Arcus Biosciences Inc. on June 24, as published by Investing.com. It indicates that the company's stock symbol is RCUS and that its price has increased by 2.48%. The content is essentially a brief announcement of the filing without furt", "url": "https://ng.investing.com/news/stock-market-news/form-4-arcus-biosciences-inc-for-24-june-93CH-2573006", "source_name": "Investing.com Nigeria", "published_at": "2026-06-25T15:09:39", "published_display": "25 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences Insider Sold Shares Worth $877,501, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/arcus-biosciences-insider-sold-shares-214857003.html", "source_name": "MT Newswires", "published_at": "2026-06-24T21:48:57+00:00", "published_display": "24 Jun 2026 21:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trust sells 25,000+ RCUS Class A shares (RCUS) in two Rule 144 transactions", "summary": "A trust has sold over 25,000 Class A shares of Arcus Biosciences (RCUS) in two separate Rule 144 transactions totaling over $686,000. These sales, occurring on June 22 and June 23, 2026, were reported under Rule 144 for secondary sales by an affiliated trust named The Juan Carlos", "url": "https://www.stocktitan.net/sec-filings/RCUS/144-arcus-biosciences-inc-sec-filing-93e6161c981d.html", "source_name": "Stock Titan", "published_at": "2026-06-24T22:09:53", "published_display": "24 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences (RCUS) president sells 31K shares under 10b5-1 plan", "summary": "Arcus Biosciences president Juan C. Jaen, through a trust, sold 31,431 shares of common stock between June 22-24, 2026, under a pre-arranged Rule 10b5-1 trading plan. The shares were sold at weighted average prices ranging from $27.03 to $29.66. Following these transactions, Jaen", "url": "https://www.stocktitan.net/sec-filings/RCUS/form-4-arcus-biosciences-inc-insider-trading-activity-a50f0e6cb69b.html", "source_name": "Stock Titan", "published_at": "2026-06-24T22:09:53", "published_display": "24 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences president sells $877,501 in company stock", "summary": "Juan C. Jaen, President of Arcus Biosciences, Inc. (NASDAQ:RCUS), sold 31,431 shares of company stock for approximately $877,501 through a Rule 10b5-1 trading plan. The sales occurred between June 22 and June 24, 2026, with prices ranging from $27.0313 to $29.6595 per share. Thes", "url": "https://www.investing.com/news/insider-trading-news/arcus-biosciences-president-sells-877501-in-company-stock-93CH-4759235", "source_name": "Investing.com", "published_at": "2026-06-24T22:09:53", "published_display": "24 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences stock hits 52-week high at $28.79", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPMFRMeTJZel84OERVcEN6LTl6NmtId19hOTFGMk1Ka21qLVRrWEItazcwMkZFNFhzc0ZPUWtacTNudzMwb3g1aThMcFg1dGNUaGt1dThwRXpTbm83YXh2ZTljZTVJeTl3am5IY3IwMUEyLXVQYmZkN2M0c1NuZHVnbER2WGFpSW5FTzV1UE13N2dUbXE4dTZMLXBGVi10Y3JxQ2RmUmxDRVY?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RCUS (NYSE) plans sale of 25,000 Class A shares on 06/22/2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOVU45WjBDYmg4dUhSaG1HUWZsWmJfeXNOYkcxOWNFRzNJVng4OHk5a0tvTEp1dWtrUlZfdkhFZ01raDd3R2Zod2pwUV9OeldOQXo4SWgxbXJaVmtKSW5sdHZhTDVtWTgtNzBRM0ZMUldIOC1ERzlvLU5BZlp2Y0FFS0NyUUtydHk1RWRKdzA3cGZKZDNfTDQ4d3ZfcXBCRjA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences (RCUS) director receives 5,700 RSUs and 16,900 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQMEdrXzJDWldHZ05wRUExcTNvc1JzZ2ZXU1JZbldmdEZ1OHpnWVFlWEhHNndSZ0I5eG9PQjNvaVR6NHc1cF9HN3duYVhLZjlKeHRmTmUyanF5UFBGbGNVVEp2ejJCbXl3STdlUzNDckJWWUtJaldPQVVHYnlQdEF6UVRaOERCeWtMM1ZQSnJIVzN5eS1PMWlyZmFjNG5Sb3dXVllVdUhnM1FPT0ZoX1NTemxVZ1ZVUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arcus-bristol-myers-team-advance-155300433.html", "source_name": "Zacks", "published_at": "2026-06-04T15:53:00+00:00", "published_display": "04 Jun 2026 15:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arcus-biosciences-partners-bristol-myers-132058875.html", "source_name": "MT Newswires", "published_at": "2026-06-03T13:20:58+00:00", "published_display": "03 Jun 2026 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences joins Goldman Sachs chat, offers live webcast June 9", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOUnhMY0VQVDlKMWNDa2lfS0dhQmRjbjdhTEU2VEFSc3JfaGxyVlNvM1o0SUl2WG9yTnpzb0pINXlVWFFCNE1SREs3OGJhRUZFdklNYnV4N1FtVHAyUzhaQjhpc01ha01HYXhTVmRXVGVhekw0aTBGYW5VcW9QQ1dUaXItZEc0TjdBdjA1c3liaTY4VGxRUkZWLUZoRG45Sm1hNEc4SzZnSmlZQ01NbFM4UHdzbU5KelFadUZVZQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arcus Biosciences, Inc. (NYSE:RCUS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences Rethinks Growth After STAR-121 Exit And Gilead Shift", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNYVFxVDBBSXpsMGJQWDVMT3FzS0xsdHFGQ3BBWWFlRzBNR3RnS3VibXEzWmRnTk41eEhLdWp6OGJya2xlMy1zUWZhMW92M3VVcy1NVU43b1dIRXd1WjNnSnBmNV9KRmVTZkZSVnhSOHFuN3Ezb1FQQmNjQ2M5NGRrNFpKcnNfaFk2dGdLYm1QR0g2a3FiUFQ5ZDZSa2IxQXRZUG8welVOSkFWaGs?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Arcus Biosciences (RCUS) After Its 221% One Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPQ0dmU3k1dXpaT1RUNVA2azl3T0VCV3hOM0pJVjJyYUt6ZmFOS3RKRm5HMFkzcGc2ZUc4cUZlVlVfOXI4Vk13eE8wTGtKbms1dFhnZF95WFdNVlBPWGh1SkN2ZnI0VGJmdHlqc0FYV1VWb25VMXFYQTBQLUFscGFNcHRlNUVhSUV5cGZFazdEaVJRVDB5VERwYWdoM1NtXzMzMUpOREpB?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQdHpyek9FWE5KZWlPeVBnZDZyc2dwMWE3ZDlsMkFlVGZFdnZEMWg4MGpzRmJRaU1ic256a212S1BOVXJnU0duV2dFR1lQa3pGTW1zdHctR3hYODE4MmJjc1JIdDFOUDc4TTk0dG9ZVHJJNlBYZUgtSnp5Q0hNVGw3WWZoNHQ4R1htNXRxZzRsV254MXpJZkc4V1RNQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arcus Biosciences stock falls on lung cancer trial halt", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNX3dyOFAyaWt4Nzd0WWFCTUJ4Nm05dDFCM1BBb3VzQXZuTDV2M3llcXE2N0hYVlVhTFpublVkbW1kSDFodS1qQ3pUWWxUMXJGQ0I2RDViN0VKampJTmdwWUFFSUQtbVJxR2liSUtwREF3cVJnZ2ZwZW9VVW13VVE3N20tU29nMElZc05iUVowM3RHSlBpMjhFLW0tSFJlZDZoU19mY2lEdjRtbmlXZ1pEQXMtcDh6MjM0?oc=5", "source_name": "Investing.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arcus Biosciences, Inc. (RCUS) Stock Price Today: $28.07", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE8wSTNieWFXdUxyYW1WYlQ3S0pZM0Z4VFNWTTIyeVVLT0kxbVYyQzgyMGZaenFvRzFhZjRRcmNuc1RtRmZ1WWp2aXg1Vk5CWTNTY2FXc2ZJRQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T01:04:16+00:00", "published_display": "13 Jan 2026 01:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQYzVzdWJUckI5Skc3SWRNNEhidUhrUkJzdlhnb05keEtWM21xRW56aXkxcG5KYjAyYmM5aFRGNk1yT0lxVmdLc0gwRS1hb3FIYVBlVm9WcGc3RlFXUGlLQ1B2VUNrY1RyZzQ3VmppRjZLaDBTb3k2WkJTbG1JYWVmZ01LMm03YzFtcTNLTlUxcFV4dnA1TExmUVVKV3dPZHozcV9FYnN1SXFDYjRPWWJTaWEyUVE2blBtUnB3LVJvR2tqWUljaG9SSm5ZMA?oc=5", "source_name": "The Motley Fool", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arcus-biosciences-host-conference-call-200500745.html", "source_name": "Business Wire", "published_at": "2026-07-21T20:05:00+00:00", "published_display": "21 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences to Discuss Cancer and Autoimmune Pipeline Aug. 5", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQNWFTeFhSNWdjY3c3YjZtX0pxdk9nb0g0NmtLSC1sYUppOERldFI1Q2NGMmtCU08xTDVScEVaN2U4ZXdzdDZOS2RKYTlScGhTR2pUX1NHWWhBRFBKSDNodzJINlVnTXN6UDNQdENBUjhEbjZPQVh1QnU2UkxOSEdINlplU2MzUlpPSDNkNjZSVTR1dGRNTXdvajQwc3ZmY1NxSzRYZEdQYXJyV1dpTTBDQThDRHlSUnVqMlNlVkFGbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T20:05:00+00:00", "published_display": "21 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?", "summary": "HC Wainwright has increased its price target for Arcus Biosciences (NASDAQ: RCUS) from $32 to $45, while maintaining a Buy rating. This adjustment reflects the company's aggressive expansion into first-line clear cell renal cell carcinoma (ccRCC) development with its drug casdati", "url": "https://www.benzinga.com/analyst-stock-ratings/price-target/26/07/60562867/arcus-biosciences-analyst-bump-price-forecast-by-33", "source_name": "Benzinga", "published_at": "2026-07-20T19:09:34", "published_display": "20 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences Jumps 5.5% After HC Wainwright & Co. Maintains Buy", "summary": "Arcus Biosciences (RCUS) saw its stock jump 5.5% to $28.88 on Monday after HC Wainwright & Co. raised its price target from $32 to $45 while maintaining a Buy rating. This bullish analyst action, coupled with increased trading volume, signifies renewed investor confidence in the ", "url": "https://news.alphastreet.com/arcus-biosciences-jumps-5-5-after-hc-wainwright-co-maintains-buy/amp/", "source_name": "AlphaStreet", "published_at": "2026-07-20T17:09:34", "published_display": "20 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 87, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises Arcus Biosciences stock price target to $45", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNb0ZFeDJRc0RPZ0xzN0VldW81clZHUXh2Yjg5b0pPWUlidGNNUXZSWkV0VU5mSHJ3eDFpY1B5UV9ZcU5BUDgzR3JNOUlocGJQS19XeDZPSXN4UjNZdmIxWHpOamx0X2tpSXkwVGtJbnJVSVh1R09BX3B5TEp3d0xfODRQSFpuLXNqRWx0cW1NTDVkbXVMcF81T3llSnd4SVgtT1ozV1d5OXE5UDZLS05hZ0t2TFJzWkJwREFyVXk1cWU?oc=5", "source_name": "Investing.com", "published_at": "2026-07-20T12:02:09+00:00", "published_display": "20 Jul 2026 12:02", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises Arcus Biosciences stock price target to $45 By Investing.com", "summary": "H.C. Wainwright has increased its price target for Arcus Biosciences (NASDAQ:RCUS) to $45 from $32, reiterating a Buy rating based on the company's progress in immuno-oncology, particularly with its drug casdatifan for clear cell renal cell carcinoma. The firm highlighted casdati", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-raises-arcus-biosciences-stock-price-target-to-45-93CH-4741659", "source_name": "Investing.com Canada", "published_at": "2026-07-20T12:09:34", "published_display": "20 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences (RCUS) Proxy filing Summary", "summary": "This article summarizes Arcus Biosciences' proxy filing from April 21, 2026, outlining key voting matters for its annual meeting on June 11, 2026. Shareholders are asked to elect four directors, ratify Ernst & Young LLP as the independent auditor, and approve named executive offi", "url": "https://quartr.com/events/arcus-biosciences-inc-rcus-proxy-filing_Fk6vjbMI", "source_name": "Quartr", "published_at": "2026-07-16T22:40:51", "published_display": "16 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Insider Has Just Sold Shares In Arcus Biosciences", "summary": "Arcus Biosciences co-founder and President, Juan Jaen, recently sold approximately US$2.0 million worth of shares at an average price of US$29.63, representing 5.9% of his total holding. While this is the largest insider sale in the past year, it occurred around the current share", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rcus/arcus-biosciences/news/this-insider-has-just-sold-shares-in-arcus-biosciences", "source_name": "Simply Wall Street", "published_at": "2026-07-15T12:10:12", "published_display": "15 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Arcus Biosciences Inc For: 13 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Arcus Biosciences Inc. on July 13th, 2026. It notes Arcus Biosciences (RCUS) stock price performance and includes general market data for various indices, commodities, and individual stocks. The publication date is sp", "url": "https://au.investing.com/news/stock-market-news/form-4-arcus-biosciences-inc-for-13-july-93CH-4530875", "source_name": "Investing.com Australia", "published_at": "2026-07-14T07:44:00", "published_display": "14 Jul 2026 07:44", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run", "summary": "Jonathan Ponciano reports on an insider sale at Arcus Biosciences, where president Juan C. Jaen sold 68,569 shares through a trust under a Rule 10b5-1 trading plan. Despite the sale, Jaen retains a significant stake of approximately 1.2 million shares. The article emphasizes that", "url": "https://finance.yahoo.com/markets/stocks/articles/arcus-insider-sold-68-569-232917867.html", "source_name": "Market source", "published_at": "2026-07-13T23:09:41", "published_display": "13 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences Insider Sold Shares Worth $2,031,919, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/arcus-biosciences-insider-sold-shares-214356143.html", "source_name": "MT Newswires", "published_at": "2026-07-13T21:43:56+00:00", "published_display": "13 Jul 2026 21:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences (RCUS) president trades 68,569 shares under 10b5-1 plan", "summary": "Arcus Biosciences President Juan C. Jaen reported the sale of 68,569 shares of common stock on July 9-10, 2026, through a trust under a Rule 10b5-1 trading plan. The sales occurred at weighted-average prices between $28.61 and $30.05 per share. Despite these sales, Jaen retains s", "url": "https://www.stocktitan.net/sec-filings/RCUS/form-4-arcus-biosciences-inc-insider-trading-activity-8e32d6cba75c.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:41:42", "published_display": "13 Jul 2026 21:41", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Arcus Biosciences For: 9 July By Investing.com", "summary": "This article announces the filing of Form 144 for Arcus Biosciences (RCUS) on July 9, by Investing.com. Form 144 filings indicate an intent to sell restricted or control securities. This brief notice provides a direct-to-the-point update regarding this specific financial action r", "url": "https://ca.investing.com/news/stock-market-news/form-144-arcus-biosciences-for-9-july-93CH-4728311", "source_name": "Investing.com Canada", "published_at": "2026-07-09T23:11:45", "published_display": "09 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trust files proposed RCUS Class A sales (RCUS) \u2014 multiple dates and amounts", "summary": "The Juan Carlos Jaen and Anita Galeana 2000 Trust has filed multiple Form 144 notices for proposed sales of Arcus Biosciences (RCUS) Class A Common Stock. These include sales on June 22, 23, 24, and July 9, 2026, totaling numerous shares and significant proceeds. The filing also ", "url": "https://www.stocktitan.net/sec-filings/RCUS/144-arcus-biosciences-inc-sec-filing-ea357c9b481d.html", "source_name": "Stock Titan", "published_at": "2026-07-09T22:10:04", "published_display": "09 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences Announces New Employment Inducement Grants", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arcus-biosciences-announces-employment-inducement-203500812.html", "source_name": "Business Wire", "published_at": "2026-07-09T20:35:00+00:00", "published_display": "09 Jul 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences awards stock options to five new employees", "summary": "Arcus Biosciences (RCUS) announced on July 9, 2026, that its Compensation Committee granted stock options and restricted stock units to five new employees. These inducement awards allow employees to purchase a total of 16,060 shares at $30.26 per share and acquire 8,080 shares of", "url": "https://www.stocktitan.net/news/RCUS/arcus-biosciences-announces-new-employment-inducement-a4qpq00phbzo.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:10:04", "published_display": "09 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences (RCUS) H.C. Wainwright 27th Annual Global Investment Conference summary", "summary": "Arcus Biosciences (RCUS) presented at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its pipeline with three programs and five Phase 3 studies, supported by significant financing from partners. A key focus is castatinopathy, a next-generation HIF2\u03b1 inh", "url": "https://quartr.com/events/arcus-biosciences-inc-rcus-h-c-wainwright-27th-annual-global-investment-conference_Fk6vzmF9", "source_name": "Quartr", "published_at": "2026-07-09T10:11:18", "published_display": "09 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences (RCUS) Gains Fresh Attention As Nature Study Puts Valuation Back In Focus", "summary": "Arcus Biosciences (RCUS) is drawing renewed attention following a Nature study on its HIF-2a inhibitor casdatifan, which showed a link between serum EPO suppression and clinical outcomes in metastatic kidney cancer. The company's stock has seen strong recent performance, with a 3", "url": "https://www.sahmcapital.com/news/content/arcus-biosciences-rcus-gains-fresh-attention-as-nature-study-puts-valuation-back-in-focus-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-05T19:41:21", "published_display": "05 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Arcus Biosciences (RCUS) Nature\u2011Published ARC\u201120 Kidney Cancer Biomarker Data", "summary": "Arcus Biosciences' Nature-published ARC-20 study data shows that casdatifan monotherapy for metastatic clear cell renal cell carcinoma links deeper HIF\u20112\u03b1 inhibition to changes in the biomarker serum EPO, with greater EPO suppression associated with higher response rates and long", "url": "https://www.sahmcapital.com/news/content/how-investors-are-reacting-to-arcus-biosciences-rcus-naturepublished-arc20-kidney-cancer-biomarker-data-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-04T19:09:07", "published_display": "04 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Arcus Bioscience (RCUS)", "summary": "This article analyzes the historical performance of investing $1,000 in Arcus Bioscience (RCUS) over various periods, showing significant returns in the last year but more modest or negative returns over longer durations. It details Arcus Bioscience's focus on developing cancer a", "url": "https://www.stocktitan.net/tools/stock-return-calculator/RCUS", "source_name": "Stock Titan", "published_at": "2026-07-04T06:40:17", "published_display": "04 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bristol-myers-squibb-bmy-joins-213544982.html", "source_name": "Insider Monkey", "published_at": "2026-07-01T21:35:44+00:00", "published_display": "01 Jul 2026 21:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RCUS - Arcus Biosciences Inc Latest SEC Filings", "summary": "This article provides a snapshot of Arcus Biosciences Inc (RCUS) with its latest financial data, key performance indicators, and market statistics as of July 1, 2026. It covers various metrics including market capitalization, income, sales, insider and institutional ownership, pr", "url": "https://finviz.com/stock?t=RCUS&ta=1&p=d&ty=lf&r=m1&page=20", "source_name": "Finviz", "published_at": "2026-07-01T20:39:08", "published_display": "01 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nature study links a kidney-cancer biomarker to casdatifan benefit", "summary": "Arcus Biosciences announced new research published in Nature, linking clinical outcomes of patients treated with the HIF-2a inhibitor casdatifan to changes in the biomarker erythropoietin (EPO). The study, ARC-20, showed that deeper suppression of serum EPO correlated with higher", "url": "https://www.stocktitan.net/news/RCUS/new-research-published-in-nature-links-clinical-activity-with-hif-2a-x90xpa3ikiee.html", "source_name": "Stock Titan", "published_at": "2026-07-01T15:10:52", "published_display": "01 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Arcus Biosciences, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold shares of Arcus Biosciences, Inc. (RCUS). It provides a detailed table including each ETF's market value, weight of RCUS stock in the fund, issuer, management style, focus, expense ratio, assets under management (A", "url": "https://www.tradingview.com/symbols/NYSE-RCUS/etfs/", "source_name": "TradingView", "published_at": "2026-06-30T04:40:04", "published_display": "30 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences, Inc. Actuals & Estimates (NYSE:RCUS)", "summary": "This article provides an overview of Arcus Biosciences, Inc. (RCUS) stock performance, analyst estimates, and financial data. It details recent stock price movements, historical highs and lows, market capitalization, and upcoming earnings dates. The company's financial actuals an", "url": "https://www.tradingview.com/symbols/NYSE-RCUS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T16:09:26", "published_display": "26 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RCUS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for Arcus Biosciences, Inc. (RCUS) stock, including analyst price targets and future predictions. It details the stock's current price, historical performance, earnings reports, revenue, market capitalization, and volatility, along with answers to ", "url": "https://www.tradingview.com/symbols/NYSE-RCUS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T09:40:21", "published_display": "26 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus awards two new employees stock options, RSUs", "summary": "Arcus Biosciences, a clinical-stage biopharmaceutical company, announced it has granted stock options and restricted stock units to two new employees. These inducement awards, totaling 18,400 options and 9,250 RSUs, were issued under the company's 2020 Inducement Plan, consistent", "url": "https://www.stocktitan.net/news/RCUS/arcus-biosciences-announces-new-employment-inducement-wyo6agvwf8c1.html", "source_name": "Stock Titan", "published_at": "2026-06-25T15:09:39", "published_display": "25 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Arcus Biosciences Inc For: 24 June By Investing.com", "summary": "This article reports on a Form 4 filing for Arcus Biosciences Inc. on June 24, as published by Investing.com. It indicates that the company's stock symbol is RCUS and that its price has increased by 2.48%. The content is essentially a brief announcement of the filing without furt", "url": "https://ng.investing.com/news/stock-market-news/form-4-arcus-biosciences-inc-for-24-june-93CH-2573006", "source_name": "Investing.com Nigeria", "published_at": "2026-06-25T15:09:39", "published_display": "25 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences Insider Sold Shares Worth $877,501, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/arcus-biosciences-insider-sold-shares-214857003.html", "source_name": "MT Newswires", "published_at": "2026-06-24T21:48:57+00:00", "published_display": "24 Jun 2026 21:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trust sells 25,000+ RCUS Class A shares (RCUS) in two Rule 144 transactions", "summary": "A trust has sold over 25,000 Class A shares of Arcus Biosciences (RCUS) in two separate Rule 144 transactions totaling over $686,000. These sales, occurring on June 22 and June 23, 2026, were reported under Rule 144 for secondary sales by an affiliated trust named The Juan Carlos", "url": "https://www.stocktitan.net/sec-filings/RCUS/144-arcus-biosciences-inc-sec-filing-93e6161c981d.html", "source_name": "Stock Titan", "published_at": "2026-06-24T22:09:53", "published_display": "24 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences (RCUS) president sells 31K shares under 10b5-1 plan", "summary": "Arcus Biosciences president Juan C. Jaen, through a trust, sold 31,431 shares of common stock between June 22-24, 2026, under a pre-arranged Rule 10b5-1 trading plan. The shares were sold at weighted average prices ranging from $27.03 to $29.66. Following these transactions, Jaen", "url": "https://www.stocktitan.net/sec-filings/RCUS/form-4-arcus-biosciences-inc-insider-trading-activity-a50f0e6cb69b.html", "source_name": "Stock Titan", "published_at": "2026-06-24T22:09:53", "published_display": "24 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences president sells $877,501 in company stock", "summary": "Juan C. Jaen, President of Arcus Biosciences, Inc. (NASDAQ:RCUS), sold 31,431 shares of company stock for approximately $877,501 through a Rule 10b5-1 trading plan. The sales occurred between June 22 and June 24, 2026, with prices ranging from $27.0313 to $29.6595 per share. Thes", "url": "https://www.investing.com/news/insider-trading-news/arcus-biosciences-president-sells-877501-in-company-stock-93CH-4759235", "source_name": "Investing.com", "published_at": "2026-06-24T22:09:53", "published_display": "24 Jun 2026 22:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences stock hits 52-week high at $28.79", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPMFRMeTJZel84OERVcEN6LTl6NmtId19hOTFGMk1Ka21qLVRrWEItazcwMkZFNFhzc0ZPUWtacTNudzMwb3g1aThMcFg1dGNUaGt1dThwRXpTbm83YXh2ZTljZTVJeTl3am5IY3IwMUEyLXVQYmZkN2M0c1NuZHVnbER2WGFpSW5FTzV1UE13N2dUbXE4dTZMLXBGVi10Y3JxQ2RmUmxDRVY?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RCUS (NYSE) plans sale of 25,000 Class A shares on 06/22/2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOVU45WjBDYmg4dUhSaG1HUWZsWmJfeXNOYkcxOWNFRzNJVng4OHk5a0tvTEp1dWtrUlZfdkhFZ01raDd3R2Zod2pwUV9OeldOQXo4SWgxbXJaVmtKSW5sdHZhTDVtWTgtNzBRM0ZMUldIOC1ERzlvLU5BZlp2Y0FFS0NyUUtydHk1RWRKdzA3cGZKZDNfTDQ4d3ZfcXBCRjA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences (RCUS) director receives 5,700 RSUs and 16,900 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQMEdrXzJDWldHZ05wRUExcTNvc1JzZ2ZXU1JZbldmdEZ1OHpnWVFlWEhHNndSZ0I5eG9PQjNvaVR6NHc1cF9HN3duYVhLZjlKeHRmTmUyanF5UFBGbGNVVEp2ejJCbXl3STdlUzNDckJWWUtJaldPQVVHYnlQdEF6UVRaOERCeWtMM1ZQSnJIVzN5eS1PMWlyZmFjNG5Sb3dXVllVdUhnM1FPT0ZoX1NTemxVZ1ZVUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arcus-bristol-myers-team-advance-155300433.html", "source_name": "Zacks", "published_at": "2026-06-04T15:53:00+00:00", "published_display": "04 Jun 2026 15:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arcus-biosciences-partners-bristol-myers-132058875.html", "source_name": "MT Newswires", "published_at": "2026-06-03T13:20:58+00:00", "published_display": "03 Jun 2026 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences joins Goldman Sachs chat, offers live webcast June 9", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOUnhMY0VQVDlKMWNDa2lfS0dhQmRjbjdhTEU2VEFSc3JfaGxyVlNvM1o0SUl2WG9yTnpzb0pINXlVWFFCNE1SREs3OGJhRUZFdklNYnV4N1FtVHAyUzhaQjhpc01ha01HYXhTVmRXVGVhekw0aTBGYW5VcW9QQ1dUaXItZEc0TjdBdjA1c3liaTY4VGxRUkZWLUZoRG45Sm1hNEc4SzZnSmlZQ01NbFM4UHdzbU5KelFadUZVZQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences, Inc. (NYSE:RCUS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences Rethinks Growth After STAR-121 Exit And Gilead Shift", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNYVFxVDBBSXpsMGJQWDVMT3FzS0xsdHFGQ3BBWWFlRzBNR3RnS3VibXEzWmRnTk41eEhLdWp6OGJya2xlMy1zUWZhMW92M3VVcy1NVU43b1dIRXd1WjNnSnBmNV9KRmVTZkZSVnhSOHFuN3Ezb1FQQmNjQ2M5NGRrNFpKcnNfaFk2dGdLYm1QR0g2a3FiUFQ5ZDZSa2IxQXRZUG8welVOSkFWaGs?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Arcus Biosciences (RCUS) After Its 221% One Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPQ0dmU3k1dXpaT1RUNVA2azl3T0VCV3hOM0pJVjJyYUt6ZmFOS3RKRm5HMFkzcGc2ZUc4cUZlVlVfOXI4Vk13eE8wTGtKbms1dFhnZF95WFdNVlBPWGh1SkN2ZnI0VGJmdHlqc0FYV1VWb25VMXFYQTBQLUFscGFNcHRlNUVhSUV5cGZFazdEaVJRVDB5VERwYWdoM1NtXzMzMUpOREpB?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQdHpyek9FWE5KZWlPeVBnZDZyc2dwMWE3ZDlsMkFlVGZFdnZEMWg4MGpzRmJRaU1ic256a212S1BOVXJnU0duV2dFR1lQa3pGTW1zdHctR3hYODE4MmJjc1JIdDFOUDc4TTk0dG9ZVHJJNlBYZUgtSnp5Q0hNVGw3WWZoNHQ4R1htNXRxZzRsV254MXpJZkc4V1RNQQ?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences stock falls on lung cancer trial halt", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNX3dyOFAyaWt4Nzd0WWFCTUJ4Nm05dDFCM1BBb3VzQXZuTDV2M3llcXE2N0hYVlVhTFpublVkbW1kSDFodS1qQ3pUWWxUMXJGQ0I2RDViN0VKampJTmdwWUFFSUQtbVJxR2liSUtwREF3cVJnZ2ZwZW9VVW13VVE3N20tU29nMElZc05iUVowM3RHSlBpMjhFLW0tSFJlZDZoU19mY2lEdjRtbmlXZ1pEQXMtcDh6MjM0?oc=5", "source_name": "Investing.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences, Inc. (RCUS) Stock Price Today: $28.07", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE8wSTNieWFXdUxyYW1WYlQ3S0pZM0Z4VFNWTTIyeVVLT0kxbVYyQzgyMGZaenFvRzFhZjRRcmNuc1RtRmZ1WWp2aXg1Vk5CWTNTY2FXc2ZJRQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T01:04:16+00:00", "published_display": "13 Jan 2026 01:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQYzVzdWJUckI5Skc3SWRNNEhidUhrUkJzdlhnb05keEtWM21xRW56aXkxcG5KYjAyYmM5aFRGNk1yT0lxVmdLc0gwRS1hb3FIYVBlVm9WcGc3RlFXUGlLQ1B2VUNrY1RyZzQ3VmppRjZLaDBTb3k2WkJTbG1JYWVmZ01LMm03YzFtcTNLTlUxcFV4dnA1TExmUVVKV3dPZHozcV9FYnN1SXFDYjRPWWJTaWEyUVE2blBtUnB3LVJvR2tqWUljaG9SSm5ZMA?oc=5", "source_name": "The Motley Fool", "published_at": "2026-01-05T08:00:00+00:00", "published_display": "05 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 55, "sentiment_summary": {"positive": 17, "negative": 8, "neutral": 30, "score": 54, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 19.6, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 27.37, "latest_week": "2026-07-17", "one_week_move": -5.4, "four_week_move": 12.6, "twelve_week_move": 7.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.954382, "market_dynamics_buy_signal": false, "relative_strength": 25.406731, "fair_value_gap": 64.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.8904, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.4% over one week, +12.6% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 10}, {"label": "Investing.com", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "Business Wire", "count": 2}, {"label": "Investing.com Canada", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 1}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-5.4% over one week, +12.6% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates"}], "updated_at": "2026-07-21T23:37:20.002802+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}